sign in sign up
<<
Home , BD (company)

Advancing the world of health BD, a history of care For over 120 years, BD has been accompanying healthcare professionals and patients, everywhere, at every moment. If you think you already know everything about BD’s BD has been shaping daily care for over 120 years • 120 years of innovation aimed at advancing the world of health. • 120 years of BD products supporting all health professionals and patients, the hale and the ailing, expertise, every day, in every care setting. • 120 years of existence, a sign of our commitment and the trust we have earned from all healthcare read no further.* system players. • 120 years of understanding and supporting changes in the world of health.

BD’s associates are committed to make a difference *But even after more than 120 years, Our teams interact with all parties: from physicians, laboratory biologists, nurses and pharmacists, to researchers, pharmaceutical firms, including all administrative and medical staff at public and we’re still learning every day. private . Each of us helps fulfil the expectations of healthcare professionals and the needs of patients. We secure the quality and availability of the products we design and manufacture, and we offer

training in their proper use to ensure optimal deployment of our solutions. In a changing environment, technological, cultural and economic evolutions interact with new health challenges to reshape our healthcare systems. Ensuring the safety of healthcare professionals and patients is BD is at the side of all healthcare professionals, making it a unique player in central to our strategy the field of medical technologies.Everyday , we join forces with researchers, A pioneer in healthcare safety engineering, BD is invested in patient safety, drawing on its long healthcare workers and patients all along the care pathway, helping them experience, its expertise, and innovations. Antibiotic resistance, healthcare-associated infections, to meet the challenges of today and prepare for the future. medication errors and laboratory testing errors are public health issues that BD works on every day.

Relying on our coverage, expertise and our exceptional relationship with the world of health that has lasted over 120 years, today we are helping transform our healthcare system, striving to improve its performance, relevance and safety. Long-standing player Patient safety in medical technology at the heart of our strategy

Worldwide coverage

Antibiotic resistance • Avoiding unnecessary antibiotic treatment • Detecting and rapidly managing multidrug-resistant $17.3 billion 70 000 $1.1 billion in turnover* associates* in annual R&D investments* Healthcare-associated infections • Confining catheter-associated and surgical-site infections • Identifying and managing patients at risk for contamination Major player in Medication errors • Making implementation and approval of medical preparations • Securing the medication-use system, from to ward • Controling complex IV administration schemes €1,209 billion 2 000 employees €22 million in turnover (including 1,700 in Pont-de-Claix)* in annual R&D investments** (including €738 million in exports)* Laboratory testing errors • Making reliable results quickly available to help make the right therapeutic decision • Limiting retests and additional, unnecessary investigation

250 1 million +250 employees each year prefilled syringes manufactured 60 years over the last 3 years** every day at our Pont-de-Claix of local activity in France 63,000 hours of employee factory** training per year***

*2019 annual report **2019 company data ***2018 company data BD: Solutions for each step on the care pathway

Doctor’s office Care center

Antibiotic resistance Hosp. center

Pharm. Services de soins 28th industry Hosp. France ranks 28th out of 33 countries laborator for the death rate Bloc opératoire Laboratory (8.61/100,000)1 testing errors Service de Private 5,600 deaths in 2015 réanimation laboratory 3 due to Centre Laboratory analytical errors infections involving d’imagerie 8 drugs resistant bacteria2 interventionnelle affect 3 out of every Factory 1,000 procedures5 Distribution center Hopital de jour Outpatients’ department Hosp. District nurse pharmacy Service des urgences

Healthcare-associated infections Research center Nursing and 1 out of 20 retirement home 1 out of 20 patients contracts an infection during a stay, which means 470,000 infected patients Medication errors and 750,000 infections per year in France3 Blood collection factory Retail 1.3 million 14 Patient’s In the , medication Around the world, home errors create harm in 1.3 million sepsis causes 20,000 deaths per day, people every year and cause at least i.e. 14 deaths per minute4 one death per day6 Our presence in the French heathcare system

Research and 2.7 million diagnostics blood cultures Administration prepared with BD media of care and Patient rehabilitation and instruments each year7 treatments and monitoring > 135 million samples drawn with BD blood collection devices (needles / collection sets) 65,500 each year7 > 60% of soft-tissue 7 out of 10 > 500 million 8 out of 10 HIV positive -dependent biopsies injections or patients infusions diabetics performed with are administered monitored with 12 7 10 7 by BD customers use BD products BD products using BD products BD products9

486 million sample tubes filled with BD devices each year7 875,000 22,500 15 million infusions per year patients with packs of medicines 40,000 leukaemia and stored each year peripheral vascular performed using BD secure interventions administration solutions for lymphomas in 7 patients receiving 7 with BD products diagnosed and monitored8 with BD systems home care7

Pharmaceutical firms around the world put their trust in us1 1: • 27 of the top 30 chose BD Medical-Pharmaceutical Systems as their partner • More than 70 of the top 100 use our products Interview with Nicolas Chandellier BD Managing Director for France

VALUES OUR STANDARDS OF BEHAVIOR Hello, Mr Chandellier. Today you are here to talk which delivers unique course offerings adapted to each “ We learn and improve to us about BD. How would you describe BD in a of our employees. Each year, 63,000 hours are spent on We do what is right few words? training within our company in France. every day. ” Nicolas Chandellier: BD is a unique player in the BD also offers a range of occupational specialities medical technology industry from a worldwide, national, providing many opportunities for career changes. We are all accountable and regional perspective. For over 120 years, BD has been Furthermore, our company also helps its talents progress exceeding 7% for over three years now. We have also accompanying healthcare professionals and patients, through career development programmes that match developed around fifteen partnerships with local, regional, everywhere, at every moment. Indeed, our presence all their aspirations for advancement. and national associations to promote and support along the care pathway is what makes us unique. We are recognized for our commitment to invest in human workforce integration for the unemployed. We thrive on innovation resources. This commitment plays out in training and and demand quality career development programs, as well as quality of life at What does BD’s environmental commitment look How does BD show its commitment to patients? work, which is a priority for us. Our company agreements like? Ensury the safety of healthcare professionals and We learn and improve bear witness to this. They reflect our resolve to innovate in Very concrete actions. For example, the site has every day patients is central to our strategy. We were pioneers matters of employment by offering our staff more choices set up 12 recycling channels, absorbing 70% of its waste. in the enhancement of safer practices by developing and flexibility, while allowing them to strike a better Over the last five years, €1.8 million of investments have solutions to protect professionals from accidental blood balance between their personal and professional lives. gone towards sustainable development. We help each exposure. Today we are tackling antibiotic resistance, other be great healthcare-associated infections, medication errors, and laboratory analytical errors. These are public How would you illustrate inclusion at BD? health issues that affect everyone, healthcare professional Inclusion and diversity together constitute one of the and patients alike. pillars of our company culture. In the name of diversity, BD has taken a stand to champion How is BD at the side of every healthcare system gender equality by supporting the advancement of BD is committed to make a difference today and tomorrow player? women’s careers, no matter the positions involved. Our goal is to muster our expertise to anticipate and address the health priorities set by public authorities. Our products are literally used everywhere, by everybody. BD is also an active member of various networks advocating greater diversity, including the Women’s Initiative Network Broad objectives defined By patients themselves, for diabetic treatment, by nurses, Tomorrow’s challenges Commitments of BD today doctors, biologists, and others. Whether the patient is (WIN). by … receiving care at home, the doctor’s office, or the hospital, BD promotes the employment of disabled individuals. To promote relevant To guide healthcare professionals towards best our solutions may be adapted to any setting and are there Our rate of employment of assocates with disabilities is far treatments and transform practices to ensure relevance of clinical procedures to help professionals as they perform their most routine higher than that legally required of us, the health system acts. This coverage affords us a complete vision of the healthcare system and the needs of all parties, but To reduce risks of To roll out solutions for infection prevention, better it also shoulders us with the responsibility to offer exposure to infectious identification of infectious agents, and protection innovations that anticipate these needs and meet  ‘Improving patient agents of patients and healthcare professionals them. safety means helping To respond to the To help improve care for patients with chronic challenges associated illnesses all along their care pathways by How are employees at the heart of BD strategy? to make the healthcare with chronic illnesses and harnessing innovation Our growth goes hand in hand with a major training their repercussions initiative, relying especially on our in-house university, system more efficient.’

Interview with Nicolas Chandellier BD Managing Director for France

What predictions might BD make tomorrow’s Treatment relevance and patient involvement are two challenges? priorities we could mention that strike a chord with us and strengthen our resolve to follow through with our I am convinced that medical devices will play a commitments. structuring role in the development of the healthcare We are ready to contribute to this transformation, system. Today already, technology provides possibilities unimaginable only ten years ago and compels us to especially since our positioning within the healthcare completely reconsider our mode of operation. Some system makes us a natural partner to help usher in these procedures previously only performed in operating rooms changes. We already work with all healthcare players and can now be carried out in doctor’s offices and may no share the same concern: to meet patients’ needs. longer even require surgery. This compels us to totally reassess the ways private practices and hospitals interact. In this regard, medical devices may help the system stop thinking in terms of places of treatment and start thinking ‘Medical devices help in terms of care pathways. Moreover, it is the ambition of the authorities to develop counter these paths, as clearly shown by the French Ma Santé healthcare system 2022 agenda, alongside other objectives closely aligned with our own. compartmentalization.’

RESPONSIBLE FOR ALL STAGES OF THE PRODUCT LIFE CYCLE

ENSURING SUPPORT R & D PRODUCTION DISTRIBUTION for implementing our PATIENT solutions SAFETY

in the hospital in the laboratory For over 120 years, BD has been accompaying healthcare at home at the pharmacy professionals and patients, everywhere, at every moment. References

1. OECD. Stemming the superbug tide: just a few dollars more. Paris: OECD Publishing; 2018.

2. Coignard B. Burden of multidrug-resistant bacteria infections, France, 2012. Study report, June 2015. Saint-Maurice: Institut de Veille Sanitaire; 2015.

3. Michel P, Minodier C, Moty-Monnereau C, Lathelize M, Domecq S, Chaleix M, Kret M, Roberts T, Nitaro L, Bru-Sonnet R, et al. Les évènements indésirables graves dans les établissements de santé : fréquence, évitement et acceptabilité [Serious adverse event in healthcare establishments: frequency, prevention, and acceptability]. DREES; 2011. No.761.

4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-10

5. Carraro P., Plebani M. Errors in a Stat Laboratory: types and frequencies 10 years later. Clin. Chem. 2007;53:7;1338-42

6. WHO launches global effort to halve medication-related errors in 5 years. WHO. 2017 Mar 29. News release.

7. Company data for fiscal year 2019.

8. - Maladies auto-immunes [Autoimmune diseases]. Paris: INSERM; [modified 2018 Jul 13; accessed 2019 Oct 18]. Advancing https://www.inserm.fr/information-en-sante/dossiers-information/maladies-auto-immunes. - Cancer Environnement. Les hémopathies malignes de l’adulte [Malignant blood diseases in adults]. Lyon: Centre Léon Bérard; 2019 [accessed 2019 Oct 18]. https://www.cancer-environnement.fr/283-Hemopathies-malignes-de- the world of health ladulte.ce.aspx. - Les hémopathies malignes se chronicisent en France [Malignant blood diseases are becoming chronic in France] Paris La Défense: Celgene; 2017 [accessed 2019 Oct 18]. https://www.celgene.fr/les-hemopathies-malignes-se- chronicisent-en-france/#. - Les chiffres des lymphomes et leucémies en France [Figures for lymphomas and leukaemia in France]. Villejuif: Fondation ARC; 2013 [accessed 2019 Oct 18]. https://www.fondation-arc.org/actualites/les-chiffres-des-lymphomes- et-leucemies-en-france. - https://www.santepubliquefrance.fr/docs/estimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en france-metropolitaine-entre-1990-et-2018-volume-2-hemopathies-maligne [Estimated national cancer incidence and mortality in metropolitan France between 1990 and 2018] Santé publique France, 2019 [accessed 2020 Feb 25].

9. Roncier C. Le VIH/sida en France en 2018. [HIV/AIDS in France in 2018]. Paris: PISTES; 2018 [accessed 2020 Feb 25]. http://vih.org/dossier/vihsida-en-france-en-2018.

10. IMS data, February 2019.

11. IQVIA-based analysis & BD Internal systems (SAP ECC, SAP Legacy, Tracis, Nodum)—2016 update.

12. Cabinet TMC 2019

Document printed on 100% recycled paper on 100% recycled printed Document

BD - 11, rue Aristide Bergès - ZI des Iles - BP4 - 38801 - Le Pont de Claix Cedex Tél : 04 76 68 36 36 bd.com/fr BD, the BD logo, BD Laboratory Consulting Services, BD Microtainer, and BD are registered trademarks of Becton, Dickinson and Company. ©2019 BD and subsidiaries All rights reserved. XEUR-0002-18WEU261